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We applaud the detail Christensen et al. 1 provide in describing the evaluation and treatment of extremely low birth weight neonates with low blood neutrophil concentrations. One significant recommendation, previously adopted for their practice guidelines, 2 involves the reasonable administration of intravenous immunoglobulin (IVIg) therapy in neutropenic neonates only with proven, or very likely bacterial sepsis and shock syndrome. This is a very important criterion that deserves further explanation.
Although the mechanism of action of IVIg in many disorders has yet to be determined, it is becoming clear that in certain disorders, such as idiopathic thrombocytopenic purpura, 3 the immunomodulatory activity of IVIg is an important component of the therapeutic effect. Only recently has the mechanism of this modulation been established as the clearance of neutrophils. Patients treated with IVIg generally experience neutropenia 4, 5 and in the case of patients with Kawasaki disease, these neutrophils are lost through an apoptotic mechanism. 6 It is now known that IVIg preparations contain autoantibodies that bind the sialic acidbinding Ig-like lectin (Siglec-9) receptor found on neutrophils. 7 In the presence of certain inflammatory cytokines, such as the rG-CSF advocated by Cristensen et al. 1 for treatment of severe chronic neutropenia, the ligation of these IVIg-provided antibodies to the neutrophil ultimately results in death of the cell. 7 As cellular apoptosis occurs without induction of inflammation, and is recognized to actively elicit systemic anti-inflammatory effects, 8, 9 this approach to managing inflammatory diseases is mechanistically sound. This appears to be a very delicate balance as IVIg treatment lacking inflammatory cytokines causes neutrophil proliferation.
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This scenario seemingly raises the question of why a therapy that reduces neutrophil populations would be advocated in certain cases of neutropenia. Is it not counterintuitive to employ a therapy that might exacerbate or prolong the neutropenia and the immunocompromised state? The answer is that the protocol advocated by Cristensen et al. 1 reserves IVIg administration for confirmed (or strongly suspected) cases of sepsis and shock, where the benefit of increased opsonic activity and exogenous antibodies against bacterial superantigens 11 outweigh the risks of suppressing, or inhibiting repopulation by, the patient's neutrophils. Managing the immune response in this manner is a delicate procedure and other conditions of neutropenia will have to be evaluated for the applicability of IVIg therapy, given this potential effect of IVIg on the repopulation of neutrophils and immune homeostasis. Nonetheless, the 100% adherence in practice to their written guidelines for IVIg use in neutropenic neonates described by Cristensen et al. 1 suggests an appropriate level of care for these neonates. Such guidelines undoubtedly provide better outcomes for patients by targeting the therapy to those most likely to benefit from it. However, it is important to state that neutropenic neonates without complications such as sepsis would likely have their immunocompromised state prolonged through IVIg and inflammatory cytokine therapy. Because of this potential detrimental effect of IVIg on the neutrophil population, great prudence is necessary in treatment of neutropenic neonates with IVIg. Buenz and Howe raise a very important point concerning the administration of intravenous immunoglobulin (IVIg) to neonates. Indeed, children with idiopathic thrombocytopenic purpura that receive IVIg can have a fall in circulating neutrophil concentration due to accelerated neutrophil clearance. Although this mechanism has not been described in neonates after IVIg administration, a somewhat similar occurrence was seen by Lassiter et al., 1 who reported neutropenia in a preterm neonate after IVIg administration, and later identified anti-neutrophil antibodies in the IVIg preparation.
Like any pharmaceutical or biological treatment employed in the neonatal intensive care unit, IVIg should be administered only when it is reasonably certain that the benefits will outweigh the risks. Septic, neutropenic neonates generally lack opsonic antibody to organisms with which they are infected. 2 Furthermore, supplying IVIg to septic, neutropenic neonates can improve their capacity to opsonize the organisms with which they are infected and can actually increase their circulating neutrophil concentrations. 3, 4 Nevertheless, we completely agree with the caution expressed by Buenze and Howe, regarding administering IVIg to neonates who have a low likelihood of infection. A temporary neutropenia, due to increased clearance of circulating neutrophils, could indeed be a consequence of some such administrations. Thus, if IVIg is to be used as a source of potential opsonins for neonates with overwhelming sepsis, 2 it should be done with the cognizance that one possible risk could, theoretically, be a prolongation of the neutropenia owing to IVIg-induced accelerated neutrophil clearance.
